AC could be described as a “gain-of-function” cancer, as most AC patients carry “gain-of-function” mutations or structural alterations in oncogenes involving the receptor tyrosine kinase pathway, such as L858R mutations in EGFR and ALK-EML4 fusion genes. The gene discussed is ALK; the disease is cancer.